enGene (NASDAQ:ENGN) Posts Earnings Results, Beats Expectations By $0.91 EPS

enGene (NASDAQ:ENGN) issued its earnings results on Monday. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.91, FiscalAI reports.

enGene Price Performance

enGene stock opened at $1.62 on Monday. The business has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $7.24. enGene has a 12 month low of $1.40 and a 12 month high of $12.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 11.75. The stock has a market capitalization of $108.52 million, a PE ratio of -0.72 and a beta of -0.29.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. UBS Group lowered their target price on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Wall Street Zen cut enGene from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Leerink Partners lowered shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 target price on the stock. in a research report on Friday, May 8th. Morgan Stanley downgraded shares of enGene from an “overweight” rating to an “equal weight” rating in a research report on Friday, May 8th. Finally, Oppenheimer lowered shares of enGene from an “outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $12.68.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENGN. XTX Topco Ltd acquired a new stake in enGene during the fourth quarter worth about $216,000. Vestal Point Capital LP lifted its position in enGene by 185.1% during the fourth quarter. Vestal Point Capital LP now owns 1,055,000 shares of the company’s stock valued at $9,527,000 after buying an additional 685,000 shares in the last quarter. Virtus Investment Advisers LLC purchased a new stake in enGene during the fourth quarter worth approximately $284,000. Quadrature Capital Ltd purchased a new position in shares of enGene in the 4th quarter valued at $439,000. Finally, Millennium Management LLC boosted its position in enGene by 7,214.0% during the 4th quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock worth $13,541,000 after purchasing an additional 1,479,018 shares during the period. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.